---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-26-000006"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:45:58.694440+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Incyte Q4 total revenue $1.51B (+28% YoY); FY 2025 net product revenue beat guidance

## Summary
- Q4 total revenue $1.51B (+28% YoY); net product revenue $1.22B (+20%). FY 2025 net product revenue $4.35B, above $4.23-4.32B guidance.
- GAAP diluted EPS Q4 $1.46, FY $6.41; non-GAAP diluted EPS Q4 $1.80, FY $6.80.
- 2026 total net product revenue guidance $4.77-4.94B, including Jakafi $3.22-3.27B and Opzelura $750-790M.
- Pipeline: positive frontMIND Phase 3 for tafasitamab in DLBCL; Jakafi XR filing submitted, decision mid-2026; INCA033989 registrational plans; ruxolitinib cream PN paused.
- Cash $3.6B; entered option agreement with Prelude Therapeutics for JAK2V617F inhibitor program ($100M option exercise).

## SEC filing metadata
- accession: 0000879169-26-000006
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/0000879169-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/incy-20260210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-26-000006
- JSON: https://secwatch.observer/filing/0000879169-26-000006.json
- Plain text: https://secwatch.observer/filing/0000879169-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.